Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

flotetuzumab (MGD006)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

MacroGenics

Drug class:

CD3 agonist, CD123 inhibitor

Related drugs:

‹

tagraxofusp-erzs (5)

CD123 targeted CAR-NK (0)

JNJ-56022473 (0)

blinatumomab (52)

epcoritamab-bysp (11)

elranatamab-bcmm (8)

tebentafusp-tebn (7)

tarlatamab-dlle (4)

mosunetuzumab-axgb (2)

talquetamab-tgvs (2)

teclistamab-cqyv (2)

glofitamab-gxbm (1)

odronextamab (1)

JNJ-63898081 (1)

CD30 biAb-AATC (0)

JNJ-63709178 (0)

JNJ-67571244 (0)

PF-06671008 (0)

PF-07062119 (0)

PF-07260437 (0)

catumaxomab (0)

UMG2-CD3 BTCE (0)

Undisclosed HER2Bi-armed ATC (0)

activated CIK and bispecific antibody (0)

activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)

ABBV-383 IV (0)

huCD33-BsAb (0)

tagraxofusp-erzs (5)

CD123 targeted CAR-NK (0)

JNJ-56022473 (0)

›

Chr t(14;21)(q22;q22)	Acute Myelogenous Leukemia	Chr t(14;21)(q22;q22)	Acute Myelogenous Leukemia	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3
TP53 mutation + Chr del(17p)	Acute Myelogenous Leukemia	TP53 mutation + Chr del(17p)	Acute Myelogenous Leukemia	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3
Chr del(17p)	Acute Myelogenous Leukemia	Chr del(17p)	Acute Myelogenous Leukemia	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3
CD123 overexpression	Acute Myelogenous Leukemia	CD123 overexpression	Acute Myelogenous Leukemia	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3
PD-L1 overexpression	Acute Myelogenous Leukemia	PD-L1 overexpression	Acute Myelogenous Leukemia	MGD006 Resistant: D – Preclinical MGD006 Resistant : D	MGD006 Resistant: D – Preclinical MGD006 Resistant : D